Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.18 USD -4.8% Market Closed
Market Cap: 580.1m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Autolus Therapeutics PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Income
-$175.5m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$171.3m
CAGR 3-Years
-154%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Operating Income
-ÂŁ174.5m
CAGR 3-Years
-80%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Income
-$196.5m
CAGR 3-Years
-45%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ59.6m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ54.2m
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
4%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
580.1m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 57%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Operating Income?
Operating Income
-175.5m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Operating Income amounts to -175.5m USD.

What is Autolus Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-1%

Over the last year, the Operating Income growth was -5%. The average annual Operating Income growth rates for Autolus Therapeutics PLC have been -1% over the past three years .

Back to Top